Pulse Biosciences, Inc.
NASDAQ:PLSE · NASDAQ Capital Market
+$0.97 today
Vol 0.36M · Avg 0.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-90.2%
avg 150.4%
ROIC
-85.7%
avg -78.9%
ROA
-75.7%
avg -70.0%
Analysis
ROA is currently the strongest return metric at -75.7% versus its period average of -70.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Darrin R. Uecker | Chief Technology Officer & Director | $869,889.00 | — | 60 | $100,000.00 | 0.14% |
Paul Arthur LaViolette | President, Chief Executive Officer & Co-Chairman of the Board | $765,068.00 | — | 68 | $15,846.00 | 0.02% |
Jon Skinner | Chief Financial Officer | $459,898.00 | — | 40 | — | — |
David Kenigsberg | Chief Medical Officer | — | — | — | — | — |
Gansevoort Dunnington | Chief Medical Officer | — | — | — | — | — |
Niv Ad | Chief Science Officer of Cardiac Surgery | — | — | — | — | — |
Steven T. Weber | Vice President of Accounting, Principal Accounting Officer & Global Corporate Controller | — | — | 50 | $0.00 | <0.01% |
Liane Teplitsky | Chief Operating Officer | — | — | 49 | — | — |
Patty Perla | Vice President of Human Resources | — | — | — | — | — |
David Danitz | Senior Vice President of Engineering | — | — | — | — | — |
Kenneth Stratton | General Counsel & Corporate Secretary | — | — | 57 | $20,000.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$27.10M
Sells
15
$5.25M
Net Sentiment
+$21.85M
Net buying
Most Active
Danahy Kevin Patrick
10 transactions
1–10 of 20
Analysis
Insiders reported 5 buys worth $27.10M and 15 sells worth $5.25M over the last 12 months. That adds up to net buying of $21.85M. Danahy Kevin Patrick was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.36B
NovoCure Limited
NASDAQ:NVCR
$1.69B
Atai Beckley Inc.
NASDAQ:ATAI
$1.49B
STAAR Surgical Company
NASDAQ:STAA
$1.43B
Immatics N.V.
NASDAQ:IMTX
$1.29B
Nektar Therapeutics
NASDAQ:NKTR
$1.17B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.12B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
Beta Bionics, Inc.
NASDAQ:BBNX
$609.16M
LifeMD, Inc.
NASDAQ:LFMD
$231.17M
Who manages PLSE?
Pulse Biosciences, Inc. (PLSE) lists 11 active executives. The top listed executive is David Kenigsberg, Chief Medical Officer.
Are PLSE insiders buying or selling?
Recent insider activity shows net buying of $249.83M.
Explore More
Continue the stock analysis
Jump to another research area for this company.